Solarea Bio Announces $11.2M in Series A
Solarea Bio Announces $11.2M in Series A Back to HomeCAMBRIDGE, MA, Solarea Bio announced it has raised $11.2M in a Series A financing led by S2G Ventures. Solarea Bio, a biotech company based in Cambridge, MA developing microbial-based solutions to aid human health, announced it has raised $11.2M in a Series A financing. The round was led by S2G Ventures and Bold Capital Partners, along with continued investment from Viking Global and additional investment from the Gisev Family Office as a syndicate investor. Solarea Bio is a biotechnology company based in Cambridge, MA developing new microbiome-based solutions to some of the world's largest health problems. Solarea was founded in 2017 by a group of scientists and entrepreneurs eager to radically alter our understanding of the human microbiome and utilize its power to improve human health.